Regulus Therapeutics reported $7.56M in Operating Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Alnylam Pharmaceuticals ALNY:US USD 598.93M 182.43M
AstraZeneca AZN:LN USD 9.74B 495M
Astrazeneca AZN:US USD 9.74B 495M
Biogen BIIB:US USD 1.19B 1.45B
Celldex Therapeutics CLDX:US USD 28.1M 8.46M
Gilead Sciences GILD:US USD 4.2B 26M
GlaxoSmithKline GSK:LN GBP 6.64B 790M
Intercept Pharmaceuticals ICPT:US USD 179.49M 94.37M
Intrexon XON:US USD 24.34M 2.74M
Lexicon Pharmaceuticals LXRX:US USD -23134000 47.18M
Ligand Pharmaceuticals LGND:US USD 65.45M 9.36M
Merk MRK:US USD 10.97B 1.31B
Omeros OMER:US USD 50.77M 13.33M
Regulus Therapeutics RGLS:US USD 7.56M 388K
Sangamo Biosciences SGMO:US USD 81.35M 6.24M
Spectrum Pharmaceuticals SPPI:US USD 21.6M 3.79M
Takeda 4502:JP JPY 897.87B 75.92B
Vital Therapies VTL:US USD 20.12M 494K
YTE INCY:US USD 684.93M 27.96M